Fellows are organized by their PI mentors, with postdoctoral followed by postbaccalaureate.
Katelyn E. Connelly, Ph.D., joined the Laboratory of Translational Genomics (LTG) in February 2019 as a postdoctoral fellow in the laboratory of Laufey Amundadottir, Ph.D., senior investigator. Dr. Connelly earned her Ph.D. in medicinal chemistry and molecular pharmacology from Purdue University in 2018. Working with Dr. Emily C. Dykhuizen, her doctoral research focused on understanding the binding and oncogenic mechanisms of the epigenetic regulator CBX8. In DCEG, Dr. Connelly is investigating the functional roles of germline variants, identified by genome-wide association studies, in pancreatic cancer risk.
Daina Eiser joined the Laboratory of Translational Genomics (LTG) in July 2018 as a postbaccalaureate fellow in the laboratory of Laufey Amundadottir, Ph.D. , senior investigator. She graduated in May 2018 from the University of Maryland, College Park, where she completed her B.S. in cell biology with a minor in computer science. Ms. Eiser previously worked as a summer intern at NCI for two years. First, she investigated protein-protein interactions in cancer cells in the laboratory of Thorkell Andresson, Ph.D. She subsequently worked under the mentorship of Jason Hoskins, Ph.D., staff scientist, in Dr. Amundadottir’s laboratory, where she studied transcription factor networks in pancreatic cancer cells. As a postbaccalaureate fellow in LTG, she continues her research on transcription factor networks in pancreatic cancer using bioinformatic tools and on finding functional variants of pancreatic cancer risk loci.
Naomi Gordon joined the Laboratory of Translational Genomics (LTG) in July 2018 as a postbaccalaureate fellow in the laboratory of Laufey Amundadottir, Ph.D., senior investigator. She graduated in May 2018 from the University of Pennsylvania, where she completed her B.A. in biological basis of behavior (neuroscience) and Hispanic studies. As an undergraduate, she worked in the laboratory of Dr. Leonard Zon at Boston Children’s Hospital to interrogate mechanisms of drug resistance in BRAFV600E-driven melanoma. She subsequently worked in the laboratory of Dr. Ben Stanger at the Perelman School of Medicine, University of Pennsylvania, to identify the mechanisms behind tumor cell-intrinsic immune suppression and the subsequent impact on response to immunotherapy. As a postbaccalaureate fellow in LTG, Ms. Gordon is currently working on finding functional variants at pancreatic risk loci and determining their role in mediating pancreatic cancer risk.
Ashley Jermusyk, Ph.D., joined the Laboratory of Translational Genomics (LTG) in March 2016 as a postdoctoral fellow in the laboratory of Laufey Amundadottir, Ph.D., investigator, LTG. Dr. Jermusyk received her Ph.D. in chemical engineering from North Carolina State University in 2016. Her doctoral research, done in the laboratory of Dr. Greg Reeves, focused on developing new approaches for understanding gene regulation using the Drosophila melanogaster embryo. Currently, her work focuses on studying the molecular mechanisms through which susceptibility variants identified by genome-wide studies (GWAS) influence the risk of pancreatic cancer.
Jun Zhong, Ph.D., joined the Laboratory of Translational Genomics (LTG) in July 2017 as a postdoctoral fellow under the mentorship of Laufey Amundadottir, Ph.D., senior investigator. Dr. Zhong completed his Ph.D. in bioinformatics from the Beijing Institute of Genomics, Chinese Academy of Sciences (BIG, CAS) in 2014, and then stayed in BIG as assistant investigator until July 2017. While at BIG, he became skilled at the use of next-generation sequencing, single-molecule real-time sequencing technology (SMRT), and whole genome methylome sequencing. His research focused on pathogenic mechanisms of human infectious disease with pan-genome and epigenetic regulation analysis. His doctoral research focused primarily on whole genome sequencing (WGS) and resequencing analysis of industrial fungus and biomedical minipigs. In DCEG, he is studying inherited predisposition to pancreatic cancer and digging out common and rare risk variants identified by genome-wide association studies (GWAS), sequence-based (WGS and transcriptome/TWAS) and other “Omic” technologies.
Jiyeon Choi, Ph.D., joined the Laboratory of Translational Genomics (LTG) in October 2011 as a postdoctoral Cancer Research Training Award fellow in the lab of Kevin M. Brown, Ph.D., investigator, LTG. In the lab, Dr. Choi is currently working on the functional characterization of common and rare genetic variants contributing to melanoma susceptibility by following up recent genome-wide association studies and family re-sequencing work. Dr. Choi has a Ph.D. in cell and developmental biology from the University of Medicine and Dentistry of New Jersey, where she pursued functional studies of autism-associated common genetic variants with Dr. James Millonig. She also has an M.S. in molecular biology from Korea University and a B.S. in biological sciences from Ewha Womans University, South Korea.
Rebecca (Becky) Hennessey, Ph.D., joined the Laboratory of Translational Genomics (LTG) in November 2018 as a postdoctoral fellow in the research group of Kevin Brown, Ph.D., senior investigator, LTG. Dr. Hennessey earned her Ph.D. in biomedical sciences from the Ohio State University College of Medicine in 2018. Her doctoral research, performed under the guidance of Dr. Christin Burd, focused on the use of melanoma mouse models to study the role of ultraviolet radiation in melanomagenesis as well as to test the efficacy of sunscreens in preventing melanoma. In LTG, Dr. Hennessy’s work focuses on utilizing screening methods to functionally characterize multiple and complex melanoma susceptibility loci that were identified via genome-wide association studies.
Hyunkyung Kong, Ph.D., joined the Laboratory of Translational Genomics (LTG) in November 2017 as a postdoctoral fellow in the lab of Kevin M. Brown, Ph.D., senior investigator. Dr. Kong completed her M.S. − Ph.D. unified course in biological sciences from Sookmyung Women’s University, South Korea. There, working with Dr. Jong Hoon Park, she focused on the genetic analysis and epigenetic mechanisms regulating drug susceptibility of breast cancer using a diverse panel of breast cancer cell lines and patient samples. In LTG, her work focuses on the functional characterization of susceptibility variants identified by genome-wide association studies, and how they influence the risk of melanoma.Scientific Publications - Hyunkyung Kong
Lindsey Mehl joined the Laboratory of Translational Genomics (LTG) in August 2017 as a postbaccalaureate fellow in the laboratory of Kevin M. Brown, Ph.D., investigator. Ms. Mehl graduated from Northwestern University, Evanston, Illinois, in June 2017 with a B.A. in biological sciences with a focus in biochemistry and biophysics. She previously worked in Northwestern University’s Pathology Department studying the interface between chronic inflammation and tumor development and metastasis in the lab of Dr. Ronen Sumagin. There, she specifically explored the role of myeloperoxidase (MPO) in inhibiting wound healing during chronic inflammation as well as the role of miRNAs secreted by polymorphonuclear neutrophils in chromatin instability and tumor heterogeneity. Currently, she focuses on characterizing the function of melanoma susceptibility gene variants that were identified via genome-wide association studies.
Andrew Vu joined the Laboratory of Translational Genomics (LTG) in October 2016 as a postbaccalaureate fellow in the laboratory of Kevin M. Brown, Ph.D., investigator, LTG. Mr. Vu graduated from the University of Michigan with a B.S. in biomolecular science in May 2016. He previously worked as a research assistant in the laboratory of Dr. Yossi Holoshitz at the University of Michigan to identify and characterize intracellular signaling pathways of the rheumatoid arthritis shared epitope. He also worked with the laboratory of Dr. Joseph M. Corey at the University of Michigan in conjunction with the Veterans Affairs Ann Arbor Healthcare System. There, he harvested and identified neuronal cells and glia with advanced growth and differentiation through the use of novel biomaterials with prospective utilization in rehabilitation after neurological injury. In LTG, Mr. Vu is working on characterizing the function of melanoma susceptibility genetic variants identified through genome-wide association studies.
Learn more about our research training opportunities in the Laboratory of Genetic Susceptibility.
Abdul Rouf Banday, Ph.D., joined the Laboratory of Translational Genomics (LTG) as a postdoctoral fellow in February 2014 and was promoted to research fellow in May 2016. Dr. Banday received his bachelor’s degree in biochemistry from University of Kashmir, India, in 2006. He received his M.Sc. (2008) and Ph.D. (2012) degrees in biochemistry, with specialization in bioinformatics, from A.M. University, Aligarh, India. For his Ph.D., he used computational and molecular biology tools to study mechanisms of alternative splicing (AS) of mouse genome kinases. In 2009, he was awarded the Council of Scientific Industrial Research Junior Research Fellowship in India and a European Science Foundation summer school fellowship for training in bioinformatics at the University of Nottingham, United Kingdom. Prior to joining NCI, Dr. Banday worked as a postdoctoral fellow in the lab of Dr. Rahul Kanadia at the University of Connecticut. He studied role of alternative splicing in mouse retinal development using both next-generation sequencing and cell biology approaches.
In LTG, Dr. Banday is working with Ludmila Prokunina-Olsson, Ph.D.,senior investigator. He is using computational and laboratory methods to explore underlying molecular mechanisms of genetic signals identified by GWAS for bladder cancer. During his time at NCI, Dr. Banday has received several awards including the NCI Director’s Innovation Award (career development), Fellows Award for Research Excellence (FARE), DCEG-FARE, AACR Scholar-in-Training Award, DCEG Intramural Research Award, and John Quale Travel Award from the Bladder Cancer Advocacy Network.
Oscar Florez-Vargas, Ph.D., M.Sc., joined the Laboratory of Translational Genomics (LTG) as a postdoctoral fellow in October 2016. Dr. Florez-Vargas earned his Ph.D. in computer science from the University of Manchester, United Kingdom, in 2016, and his M.Sc. in biochemistry from the National University of Colombia in 2008. For his doctoral research, he developed computer-based strategies for reviewing biomedical scientific manuscript methods and predicting their reproducibility under the mentorship of Professors Andy Brass and Robert Stevens. His master research focused on identifying microRNAs associated with pharmacologically-induced senescence in an in vitro model of melanoma. In LTG, Dr. Florez-Vargas is working with Ludmila Prokunina-Olsson, Ph.D., senior investigator, on multiple genomic regions that have been associated via GWAS with increased risk of several cancers. He is involved in computational analysis of genotype-phenotype relationships to further evaluate the contribution of specific genomic regions, genes, and genetic variants to cancer phenotypes. Prior to joining LTG, Dr. Florez-Vargas was involved as a researcher in a number of studies examining genetic associations with infectious diseases and toxicological exposures in Colombia.
Seraph Lin joined the Laboratory of Translational Genomics (LTG) in July 2017 as a postbaccalaureate fellow in the laboratory of Ludmila Prokunina-Olsson, Ph.D., senior investigator. She earned her B.M. in piano performance with a minor in education from the University of California, Irvine in 2013, attended Pasadena City College from 2014–2017, and currently attends the University of Maryland, College Park, as a Science in the Evening (SIE) postbaccalaureate student. Ms. Lin first joined the Prokunina-Olsson lab in 2016 as a Community College Summer Enrichment Program (CCSEP) intern, where she worked on isoform specificity in APOBEC mutagenesis. She is currently investigating genome-wide association study (GWAS)-identified genomic regions associated with bladder cancer risk, and regulation of APOBEC mutagenesis in cancer.
Nina Rao, B.S., joined the Laboratory of Translational Genomics (LTG) in August 2017 as a predoctoral fellow through the NIH-Johns Hopkins Graduate Partnership Program. After graduating with a B.S. in biochemistry and molecular biology from the Pennsylvania State University, Ms. Rao spent a year as a postbaccalaureate fellow in the laboratory of Dan Fowler, M.D., Center for Cancer Research, NCI. There she studied the effects of rapamycin on T cell-based therapies for blood malignancies. Ms. Rao then joined the laboratory of Ludmila Prokunina-Olsson, Ph.D., Chief and senior investigator, LTG, as a postbaccalaureate fellow, where she worked for two years on the functional characterization of the novel interferon, IFN-λ4. As a current graduate student in LTG, Nina is mentored by Dr. Prokunina-Olsson and Michael Dean, Ph.D., senior investigator. She studies genetics and molecular epidemiology of bladder cancer, currently focusing on factors affecting APOBEC mutagenesis.
Joselin Vargas joined the Laboratory of Translational Genomics (LTG) in June 2017 first as a summer intern through the NCI Introduction to Cancer Research Careers (ICRC) program, and then as a postbaccalaureate fellow in the laboratory of Ludmila Prokunina-Olsson, Ph.D, senior investigator. Ms. Vargas earned her B.S. in biology with a minor in leadership development from Stony Brook University, New York, in 2017. Working with Dr. Gerardo G. Mackenzie, she focused her undergraduate research on pancreatic cancer and performed in vitro testing of a novel drug alone and in combination with FDA-approved drugs. In 2014, she worked in the laboratory of Dr. Ruel Desamero, where she identified the molar extinction coefficient and emission of phenylalanine amino acid derivatives to access the role of aromatic residues in driving amyloid formation. In the Prokunina-Olsson lab, Ms. Vargas is exploring a novel interferon (IFNL4) and its association with infection and cancer.
Fang Wang, Ph.D., joined the Laboratory of Translational Genomics (LTG) as a postdoctoral fellow in June 2015. Dr. Wang received her Ph.D. in pathobiology and molecular biology from Tianjin Medical University, China in 2011. Her doctoral research focused on the role and mechanisms of tumor-associated genes, including miRNAs, in tumorigenesis and tumor progression. In LTG, Dr. Wang is working under the mentorship of Ludmila Prokunina-Olsson, Ph.D., senior investigator. She is involved in exploring genetic and functional connections of a novel interferon (IFNL4) with infection-associated cancers. She is also working on the molecular phenotypes of several regions that have recently been associated with increased risk of bladder cancer through genome-wide association studies (GWAS).